Welcome to our dedicated page for Nascent Biotech news (Ticker: NBIO), a resource for investors and traders seeking the latest updates and insights on Nascent Biotech stock.
Nascent Biotech, Inc. (NBIO) generates news primarily through developments in its clinical programs, collaborations, and corporate updates related to its lead monoclonal antibody candidate, Pritumumab (PTB). As a clinical-stage biotechnology company focused on cancer therapeutics, many of its announcements center on progress in brain cancer research, particularly glioblastoma, and on regulatory and scientific milestones.
News coverage for NBIO often highlights key clinical events, such as completion and presentation of Phase I trial data, FDA clearance to begin Phase II clinical trials for brain cancer, and updates on Phase II planning and study design. The company also issues press releases when it presents data at major scientific meetings, including poster presentations that summarize safety findings and early signs of biological activity.
Another important category of Nascent Biotech news involves strategic collaborations. The company has announced a research collaboration with Manhattan BioSolutions to explore antibody-drug conjugates using Pritumumab as the targeting antibody, and a collaboration with HypoSpray Pharma to investigate alternative transdermal and transmucosal delivery approaches for PTB. These stories provide insight into how Nascent aims to expand PTB’s potential applications and delivery options.
Investors following NBIO will also see corporate and capital-structure updates, such as the company’s disclosure that it fully repaid a variable convertible note to remove related dilution risk, and its later notice about a filing delinquency that led to quotation on the OTC Markets’ Expert Market. Together, these news items offer a view into both the scientific and financial aspects of Nascent Biotech’s development. This page aggregates such releases so readers can track clinical progress, partnership activity, regulatory milestones, and trading-status updates over time.
Nascent Biotech (OTCQB:NBIO) has received a notification from OTC Markets Group due to failing to file its Q3 2024 Form 10-Q on time. As a consequence, the company's stock has been moved from regular OTC Markets platforms to the 'Expert Market.' The company is actively working with auditors and legal advisors to complete the delayed filing and return to compliance with OTC Markets' listing requirements.
CEO Sean Carrick stated the company is committed to resolving the situation promptly and maintaining transparency. Once the filing requirements are met, NBIO expects its stock to resume normal quotation on OTC Markets' trading platforms.
Nascent Biotech (OTCQB:NBIO) presented at the Emerging Growth Conference on July 18, 2024, highlighting its progress in developing Pritumumab (PTB), a monoclonal antibody targeting various cancer types. CEO Sean Carrick discussed:
1. PTB's successful Phase I results and safety profile
2. Plans for Phase II trials focusing on brain cancer, with potential expansion to pancreatic and colorectal cancers
3. Timeline for manufacturing completion by year-end and Phase II trials starting in Q1 2025
4. The company's de-risked investment profile and need for funding to advance clinical trials
Nascent aims to begin expanded access trials for digestive cancers in Q2 2025, leveraging PTB's potential across multiple cancer types.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Nascent Biotech (NBIO)?
What is the market cap of Nascent Biotech (NBIO)?
